The Companies to Watch column spotlights small, entrepreneurial biopharma companies that are developing their own products (not just a platform) with little or no press coverage to date, and offering an interesting story involving useful business lessons.
With 24 employees, Paris-based Abivax is in Phase 2 clinical development of its lead drug candidate, which is a potential functional cure for HIV infection. It has also recently spawned an early clinical program in inflammatory bowel disease (IBD).
Madrigal Pharmaceuticals is taking on NASH and other liver diseases by targeting the thyroid hormone beta receptor. The company expects to begin seeing top line Phase 2 trial results in late 2017, with more released in 2018.
By early 2016, Arena’s board decided to remake the company, beginning with new management and a new strategy. Since then, the company has evolved back to a core drug development platform.
ProMIS Neurosciences believes inaccurate targeting of mAbs is to blame, in fact, for lack of progress against Alzheimer’s disease.
Outside skepticism about GeNeuro’s scientific concept has made fund-raising even harder than usual for a startup. But the Swiss company has found considerable support in Europe.
Frequency Therapeutics is an early-stage developer of small molecule drugs to activate “progenitor cells” and restore healthy tissue. Its lead program is in treating hearing loss by regenerating sensory cells in the inner ear, for which it is planning a Phase 1 trial to launch in mid-2018.
To heal the wounds — maintaining and restoring cellular homeostasis with novel secretomes.
An anti-infective immunotherapy developer on a mission to replace antibiotics with engineered antibodies and novel mechanisms.
In Phase 3 with an innovatively delivered drug to treat a deadly complication of ruptured brain aneurysm.
There is no grand plan for a whole year of Companies to Watch (CtW). Each month, a single candidate makes the cut for a single column. Nevertheless, patterns emerge among the CtWs as the year progresses and come into focus as it ends.
Can women leaders be responsible and liked – at the same time? Sophie Kornowski-Bonnet, head of Roche partnering, discusses her approach to overcoming adversity, leading to an interesting discussion on if there are differences beyond gender for male versus female executives.
What’s it take to get to the c-suite of a biopharmaceuticals company? For Sophie Kornowski-Bonnet, it was a willingness to step out of her comfort zone. The current head of Roche partnering and executive committee member, shares her intriguing career path, which began in Paris, France, back in 1986.
Prior to joining Lilly as SVP of clinical and product development, Daniel Skovronsky, M.D., Ph.D. was CEO of Avid Radiopharmaceuticals — a company he founded while still a graduate student. This article is a prequel to the upcoming feature in our November issue that explores how he built a $300 million company.
Merck’s SVP of BD and licensing, Ben Thorner, provides insight into what type of deals to expect at the 36th Annual J.P. Morgan Healthcare Conference.
Seven tips to get you ready for attending the 36th Annual J.P. Morgan Healthcare Conference.